MSLN and neoplasm: Similar results were obtained in another phase I study in fifteen enrolled adult patients with measurable MSLN+ (≥10% of tumor cells expressing MSLN) locally advanced or metastatic solid tumors who failed at least one standard therapy or were unable to tolerate chemotherapy [131].